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Abstract
Background: Epigenome-wide association scans (EWAS) are under way for many com-
plex human traits, but EWAS power has not been fully assessed. We investigate power
of EWAS to detect differential methylation using case-control and disease-discordant
monozygotic (MZ) twin designs with genome-wide DNA methylation arrays.
Methods and Results: We performed simulations to estimate power under the case-
control and discordant MZ twin EWAS study designs, under a range of epigenetic risk
effect sizes and conditions. For example, to detect a 10% mean methylation difference
between affected and unaffected subjects at a genome-wide significance threshold of
P¼1 106, 98MZ twin pairs were required to reach 80% EWAS power, and 112 cases
and 112 controls pairs were needed in the case-control design. We also estimated the
minimum sample size required to reach 80% EWAS power under both study designs.
Our analyses highlighted several factors that significantly influenced EWAS power,
including sample size, epigenetic risk effect size, the variance of DNA methylation at the
locus of interest and the correlation in DNA methylation patterns within the twin sample.
Conclusions: We provide power estimates for array-based DNA methylation EWAS
under case-control and disease-discordant MZ twin designs, and explore multiple factors
that impact on EWAS power. Our results can help guide EWAS experimental design and
interpretation for future epigenetic studies.
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Introduction
Recent advances in epigenetic technologies have
enabled high-throughput epigenome-wide association
scans (EWAS). To date EWAS have predominantly
focused on DNA methylation, identifying many
differentially methylated positions (DMPs), differentially
methylated regions (DMRs) and allele-specific
methylation (ASM) regions,1,2 related to ageing,3–6
environmental exposures7–11 and complex diseases.12–14
The majority of EWAS use microarray-based DNA
methylation platforms, such as the Illumina Infinium
HumanMethylation450 (Illumina 450K15) array.
Several methods have recently been developed to explore
epigenome-wide variation,16–23 but limited research has
investigated power.
Similar to genome-wide association scans (GWAS), in
EWAS power depends on several key factors including study
design and sample size, effect size and correction for mul-
tiple testing. At least two additional factors that are specific
to epigenetic data can also influence power, and these are
the longitudinal stability of the epigenetic marks and their
variance within a biological sample, because epigenetic sig-
nals in a biological sample from one individual represent fre-
quency measures from a population of cells. Although most
of these factors remain unknown, results from recent EWAS
can provide some insights. The two most widely applied
EWAS study designs to date are the case-control and the dis-
ease-discordant monozygotic (MZ) twin design, which is
often sought after because twins are closely matched for
genetic variation, age, sex and cohort effects, and have simi-
lar early environments. Recent EWAS findings based on
these designs report modest to moderate effect sizes of
0.13% to 6.6% difference in DNA methylation levels be-
tween affected and unaffected individuals in type 1 dia-
betes,24 10% in pain,10 >10% difference in systemic lupus
erythematosus (SLE)25 and up to> 20% for environmental
exposures such as smoking.11 To correct for multiple test-
ing, recent EWAS have applied Bonferroni correction on the
total number of regions and false-discovery rate (FDR)
approaches. Longitudinal stability of epigenetic variants has
been explored genome-wide, and appears to vary across re-
gions and among individuals of different ages.4,26
Lastly, the impact of biological variability in epigenetic
marks within a sample has been recently addressed
in the context of whole blood cell composition, where
it is now widely acknowledged that blood cell
heterogeneity can impact on EWAS results, and computa-
tional methods have been developed to minimize these
effects.22,23
Although power has a crucial role in EWAS, only two
recent studies have addressed it in detail in the context of
the case-control study design.27,28 In both studies, the
authors estimated power under a number of assumptions
and for a range samples sizes, and concluded that the
distribution and variability of DNA methylation at
the locus of interest can impact on power to detect small
effect sizes. Greater power was attained at loci where the
DNA methylation signal was less variable in both case and
control groups. Furthermore, the studies also propose new
measures of effect size (for example, the methylation odds
ratio27) and extended EWAS test statistics.28 In the dis-
ease-discordant MZ twin design, formal power calcula-
tions are still lacking, but several studies have estimated
locus-specific power estimates.3,29–30 These are based on
different technologies and under a number of assumptions,
and report a wide range of power. For example, 25 twin
pairs were sufficient to reach 80% power to detect a 1.2-
fold change in DNA methylation at Bonferroni correction
in CpG island microarray (not single-CpG resolution)
methylome data,29 whereas more recent examples report
low (35%) to good (>80%) power to detect DMRs at sin-
gle CpG sites with methylation differences of 5–6% be-
tween affected and unaffected twins in 20–22 disease-
discordant twin pairs.3,30
Here, we estimate power of EWAS to detect the differen-
tial methylation using methylation platforms such as the
Illumina 450K, under the case-control and disease-discordant
twin study designs. We also evaluate the sample size required
to reach 80% power under a variety of effect sizes for the
two study designs. We explore factors that impact on EWAS
Key Messages
• We provide estimates of EWAS power using simulations based on DNA methylation array data.
• EWAS power was calculated under both the case-control and discordant MZ twin designs.
• We explore major factors that influence EWAS power including sample size, effect size (methylation difference and
methylation odds ratio), the methylation variance of the case and control samples, and the correlation in DNA methy-
lation between identical twin pairs.
• The provided power estimates can help guide EWAS study design and interpretation.
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Figure 1. DNAmethylation patterns at the (A) cellular and individual levels, and (B) with respect to the proposed methylation distributions in the simu-
lations. We assume that a cell can have two methylated alleles (ei¼ 1), one methylated allele (ei¼ 0.5) or two unmethylated alleles (ei¼ 0), and one
sample from an individual contains different frequencies of these cells (A, upper panel). The methylated allele is shown as a dagger symbol, and the
colour of each cell represents its methylation status: un-methylated (white), hemi-methylated (grey) and methylated (black) (A, upper panel). The
methylation in each sample is represented as the summary of the methylated epi-allele, denoted here as beta (A, middle panel) which can range from
0 to 1 (A, lower panel). We assume that cases have greater mean methylation levels compared with controls, and we propose one control and eight
case distributions. (B) Each line represents the density of methylation levels on each proposed distribution, where the Control distribution is un-
methylated, Cases 1–3 represent predominantly un-methylated samples (left panel), Cases 4–6 are hemi-methylated (middle panel) and Cases 7–8
are predominantly methylated (right panel).
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power, such as the effect size, between-group methylation
variance and the methylation correlation in twins.
Methods
An epigenetic model of complex disease
susceptibility
We assume that disease risk is affected by DNA methyla-
tion at a single locus, l (Figure 1A, upper panel), where
l represents a single CpG site in the genome. The methyla-
tion status at locus l in a single cell can be represented as
a biallelic marker, where epi-allele 1 represents the pres-
ence of the methylated mark, and epi-allele 0 represents
the absence of methylation. We assume that the disease-
associated methylation mark occurs prior to onset of
disease and is faithfully transmitted through mitotic
cell division. We denote DNA methylation status
(epi-genotype) at locus l as ej, where the ej takes the value
of 0, 0.5, and 1 to correspond to un-methylated, hemi-
methylated and methylated states for a single cell. Each in-
dividual cell can consist of un-methylated, hemi-methy-
lated and methylated epi-genotypes with probabilities of
p1, p2 and p3, where p1þ p2þ p3¼ 1. A sample from an
individual i represents a population of cells (Figure 1A,
middle panel), and we assume that the contribution of
each cell to the population is constant and without bias.
The sample-level DNA methylation estimate is a func-
tion of the methylation levels of the composition of cells
(Figure 1A, lower panel), and can be described by different
functions or epigenetic models. In this study, we propose a
threshold model where the sample-level DNA methylation
estimate reflects the allele frequency of the methylated epi-
allele 1 in the cell population. That is, DNA methylation
level for each sample is denoted as b (beta), which repre-
sents the sum of its fully methylated cells plus half of its
hemi-methylated cells, divided by the total number of cells
in the sample. In addition to the proposed DNA methyla-
tion threshold model, dominant and recessive models may
also be applied, as proposed for genetic disease susceptibil-
ity risk.
DNA methylation distribution
Multiple methods can be used to profile DNA methylation
patterns across the genome. We focus on micro-array
based datasets, such as those generated by the Illumina
450K array, which is currently the most widely used gen-
ome-wide technology to detect methylation in large-scale
EWAS. The array measures methylated and un-methylated
signals at 485 578 single CpG sites genome-wide. At each
CpG site, the Illumina 450K DNA methylation level is
characterized as a finite bounded quantitative trait b,
calculated as:
Beta bð Þ ¼ Methylated signal
Methylated signal þUnmethylated signal þ 100
Previous work has proposed that a single or bimodal
beta distribution can be used to describe the single-locus
distribution of DNA methylation levels on the Illumina
450K array.27 We therefore propose nine single-locus
DNA methylation distributions in the context of the epi-
genetic disease susceptibility model. We assume that the
absence of methylation is linked to the absence of disease,
and propose an un-methylated distribution in unaffected
individuals (Control distribution, Figure 1B), which is
described by b(1.5,6) with a mean methylation level of 0.2.
In our model, affected individuals will show higher levels
of DNA methylation relative to controls, and we propose
eight possible single-locus methylation distributions in af-
fected individuals (Case 1–Case 8 distributions, Figure 1B).
The eight case distributions have increasing ordinal mean
methylation difference with the control distribution that
ranges from 1% to 60% in mean DNA methylation. The
eight case distributions include three distributions (Case
1–Case 3) with mean methylation levels 0.3 (un-
methylated), three distributions (Case 4–Case 6) with
mean methylation levels 0.45 and 0.5 (hemi-methy-
lated) and two distributions with mean methylation
levels 0.75 (methylated). The three proposed un-methy-
lated case distributions, Case 1 to 3, follow b(1.6,6), b(2,6)
and b(2.6,6) with a mean methylation level of 0.21, 0.25
and 0.30, respectively, and mean methylation difference of
1%, 5% and 10% with the control distribution, respect-
ively. Case 4 and Case 5 characterize hemi-methylated dis-
tributions of b(4.9,6) and b(6,6) with mean methylation
levels of 0.45 and 0.5, respectively, and mean methylation
differences of 25% and 30%, respectively. Case 6 is also
hemi-methylated, but follows the normal distribution
N(0.5,0.1), and has the same mean methylation level as
Case 5 but a smaller standard deviation. Case 7 follows the
combination of 9% of b(1.5,6) and 91% of b(6,1.5) with a
mean methylation of 0.75, and methylated Case 8 follows
the b(6,1.5) with a mean of 0.8 that is diametrically
opposed to the control distribution. The mean methylation
difference between Case 7 and Case 8 with the control dis-
tribution was 55% and 60%, respectively.
Study designs
Power was estimated under two EWAS study designs, case-
control and disease-discordant monozygotic (MZ) twins.
To compare power under the same parameters in the
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case-control and twin designs, we assumed that cases were
identical in both study designs, and their matched controls
and unaffected co-twins were sampled from the control
distribution. In case-control design, the controls were se-
lected based on the defined effect sizes. In the MZ discord-
ant twin design, unaffected co-twins were selected with
additional intra-pair locus-specific correlation. In each
simulation, cases were selected from one of the eight Case
distributions, and for the disease-discordant MZ twin
design unaffected co-twins were sampled from the control
distribution if: (i) the mean difference within the co-twins
matched the pre-specified effect size; and (ii) the
Spearman’s correlation coefficient within MZ pairs was
between 0.193 and 0.616, which represented the
genome-wide mean correlation coefficients6 1 SD in a
previously published set of 21 MZ twins using Illumina
27K.3 Once MZ twin pairs were selected, for each affected
twin (or case) we also sampled a matched healthy unrelated
control sample from the control distribution. Figure 2
shows an example simulation procedure by selecting the
cases from distribution Case 3 and both matched unrelated
controls and matched healthy co-twins from the control
distribution.
Simulation parameters
We considered case-control and disease-discordant twin
samples over a range of sample sizes. As MZ twins are
more difficult to recruit than unrelated cases and controls,
we used a smaller sample size for the twin design, specific-
ally 10, 15, 20, 25, 30 and 50 MZ twin pairs. Power calcu-
lations were also performed for case-control sample sizes
of 10, 15, 20, 25, 30, 50, 100, 200 and 500 pairs of unre-
lated cases and controls (that is, altogether 20 to 1000 indi-
viduals in the sample).
As an estimate of effect size we used two approaches.
First, we used the mean difference in methylation levels
between affected and unaffected individuals, which ranged
from 1% to 20%, 25%, 30%, 55% and 60%, and this
was applied to both the twin and case-control designs. The
selection of effect sizes and sample sizes was based on
recently published EWAS findings as described in the intro-
duction, and further extended to cover a broad range. In
our simulation results (Supplementary Table 1a–c, avail-
able as Supplementary data at IJE online), we did not have
power to detect effects at 1% methylation difference at sin-
gle locus significance (P<0.05) with 500 cases and con-
trols, and therefore the simulations with methylation
differences less than 1% were not performed. For the case-
control design we also calculated effect sizes using the
methylation odds ratio (methOR). Given the pre-specified
range of mean methylation differences (1% to 60%),
we calculated the methOR, which was previously27
defined as:
methOR
¼ Mean MethylationCase  ð1Mean MethylationControlÞ
1Mean MethylationCaseð Þ  Mean MethylationControl
The methOR in this study ranged from 1.05 to 2.0, and
was combined with a maximum mean difference value to
minimize methylation effect variability, because the range
of mean differences tends to be narrower for larger sam-
ples. For example, for a methOR¼1.2, the range of mean
differences is 2.63% to 3.68% in 50 case-controls, whereas
the range is 2.78% to 3.38% in 500 case-controls. In this
example, to reduce bias caused by variation of mean differ-
ence, we set a cutoff of 3% mean difference along with
methOR¼ 1.2.
We estimate the variance in DNA methylation signal
using the pooled standard deviation (pooled SD) of each
case-control or twin sample by calculating:
Pooled SD ðSDCase;ControlÞ
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
NCase  1ð Þ  SDCase2 þ ðNControl  1Þ  SDControl2
ðNCase þNControl  2Þ
s
We also assessed the correlation in DNA methylation pro-
files between cases and controls, and between affected
twins and healthy co-twins. We calculated between-group
correlation using Spearman’s correlation coefficients (q).
The statistical significance threshold was set at a
P-value threshold of 0.05 for single locus analysis, and
a P-value threshold of 1 106 for genome-wide signifi-
cance. This threshold was selected using Bonferroni
correction based on a subset of the probes on the Illumina
450K array, because some regions show evidence
for co-methylation. Furthermore, recent EWAS using
Illumina 450K data have reported FDR-based thresholds
of 1% to 5% FDR with corresponding P-values close to
P¼ 1  104.31,32
Estimation of statistical power
Power estimation was based on simulations. For the para-
metric analyses, a t test with a prior F test for equal vari-
ance was performed in the case-control design and a paired
t test was performed in the twin study design. All of the
case-control simulations include equal and unequal varian-
ces between cases and controls with the exception of one
case-multiple control scenario with a greater proportion of
unequal variances. Supplementary Tables 1a–c show
results from simulations with equal variances between
cases and controls. The corresponding nonparametric ana-
lyses, Wilcoxon rank sum test (also called the
International Journal of Epidemiology, 2015, Vol. 44, No. 4 1433
 at K
ing's College London - Journals D
ept on January 8, 2016
http://ije.oxfordjournals.org/
D
ow
nloaded from
 
Mann–Whitney U test) and Wilcoxon signed rank test,
were also performed. All statistical analyses were per-
formed in R version 2.15.0.
Results
Power of case-control EWAS using mean
difference effect estimates
Power simulations were performed under the case-control
EWAS design, by sampling effect sizes based on the mean
difference in DNA methylation between cases and controls.
Cases were selected from one of eight case distributions and
controls were drawn from the control distribution, using
1000 permutations per simulation. Simulations were per-
formed with mean difference effects from 1% to 60% and
with increasing sample sizes from 10 to 500 pairs of cases
and controls, that is, 20 to 1000 individuals altogether
(Figure 3A, Supplementary Table 1a, available as
Supplementary data at IJE online). Figure 3A shows the
mean difference required to achieve 80% power at different
sample sizes at P-value thresholds of 0.05 (single locus
threshold, upper plot) and 1 106 (genome-wide
threshold, lower plot). For example, a sample size of 100
cases and 100 controls results in over 80% power to detect
a 4.5% mean difference (mean methOR¼ 1.32) in methyla-
tion at nominal significance (P¼ 0.05). However, at a gen-
ome-wide significance (P¼1106) the same sample size
gives over 80% power to detect a much larger effect size of
11% mean difference (mean methOR¼ 1.81). The results
of the Wilcoxon test are shown in Supplementary Table 1
and 2, available as Supplementary data at IJE online. We
also performed power estimation under the one case-mul-
tiple controls scenario. We show results from one case:two
controls and one case:four controls study design
(Supplementary Table 1b and c, available as Supplementary
data at IJE online) and, as expected, power increases when
the sample size of the control group increases.
Power of case-control EWAS using methOR
effect estimates
We next considered using the methOR as a measure of ef-
fect size in the case-control design. Power estimates were
obtained from simulations with methOR effects of 1.05 to
Figure 2. Example of a permutation procedure. Cases were drawn from the case distribution and matched controls, and healthy co-twins were drawn
from the control distribution. Only permutations with a set effect size between the two groups were used in the power calculation. The cases are iden-
tical for both case-control and twin designs (black dots). Controls in the case-control design were randomly selected from the control distribution. In
the twin design, DNA methylation profiles in healthy co-twin controls were correlated with cases (Spearman’s correlation coefficients between 0.193
and 0.616). The thickness of the blue line in the twin design illustrates the similarity in DNA methylation between twins.
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2.0 and with increasing sample sizes from 50 to 500 pairs
of cases and controls (Figure 3B, Supplementary Table 2
available as Supplementary data at IJE online). To achieve
80% power to detect differential methylation at nominal
significance, the minimum methOR that could be detected
ranged from 1.15 for a sample of 500 cases and 500 con-
trols, to 1.45 for a sample of 50 cases and 50 controls. To
achieve 80% power to detect differential methylation at
genome-wide significance, sample sizes of at least 100
cases and 100 controls were required to detect methORs of
at least 1.8, and no power was observed for smaller sam-
ples (n50 cases and 50 controls).
Power of discordant twin EWAS
We next estimated EWAS power under the disease-discord-
ant MZ twin design. Simulations were performed with
mean difference effects from 1% to 60% and with sample
sizes of 10, 15, 20, 25, 30 and 50 twin pairs (Table 1,
Figure 4). For example, we observed that a sample of 25
twin pairs has over 80% power to detect a mean difference
of 8% in methylation at nominal significance (P¼ 0.05),
and 25% at genome-wide significance (P¼ 1 106). As
expected, power estimates in twins outperformed the case-
control design (Table 1, Figure 4). For example, a sample
of 25 twin pairs has over 80% power to detect a mean dif-
ference of 8% in methylation at nominal significance
(P¼ 0.05), whereas 25 pairs of cases and controls have
only 45% power to detect this effect (Figure 4A). At gen-
ome-wide significance, at least 50 pairs of subjects were
required to identify effect sizes of 16% mean difference
with over 80% power in both designs (Figure 4B).
However, our simulations were not designed for a formal
comparison between case-control and twin power, because
our results assume that twins and case-control samples are
equally well matched for factors that can influence
Figure 3. Power of case-control EWAS. Estimates are obtained for a range of sample sizes, using (A) mean difference and (B) methOR effects, at nom-
inal (upper panel) and genome-wide (lower panel) significance thresholds. Each line represents the power curve under different case-control sample
sizes from 10 to 500 pairs of cases and controls.
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differential methylation, including age, sex and cohort ef-
fects, and unrelated samples are typically more heteroge-
neous than MZ twins.
Sample size required to reach 80% power in
EWAS twin and case-control designs
We estimated the sample size required to reach 80%
power in both the twin and case-control designs (Table 2).
Effects were simulated using mean differences of 7% to
15% for both case-controls and twins. Power was
estimated at nominal significance (P¼ 0.05) and at a
EWAS genome-wide significance threshold of
P¼ 1 106. Twins required a smaller sample size to
reach 80% power compared with case-controls. In general,
the sample sizes required to detect larger mean differences
(13%) were similar between twins and case-controls, but
differed when mean differences were smaller (10%).
For example, to detect a mean difference of 7% at gen-
ome-wide significance, 178 pairs of twins were required
and 211 cases and 211 controls were needed. Similar
sample sizes were estimated using the nonparametric
Wilcoxon test.
DNA methylation variance can impact on power
in the EWAS case-control design
We explored the effect of DNA methylation variance on
EWAS power by estimating the pooled SD in DNA methy-
lation for the combined case-control sample as a measure
of variance (Figure 5A). We selected permutations with 20
cases and 20 controls at a 10% methylation mean differ-
ence and with equal variances, and estimated power by
categorizing the pooled SD into four groups (0.145–0.150,
0.150–0.155, 0.155–0.160 and 0.160–0.165) and methOR
into six groups (1.62–1.64, 1.64–1.66, 1.66–1.68,
1.68–1.70, 1.70–1.72 and 1.72–1.74). Power was esti-
mated using the t test (Figure 5A, left panel) and Wilcoxon
test (Figure 5A, right panel) at nominal significance. Under
the t test, the pooled SD greatly influences power where
greater pooled SD will lead to lower power irrespective of
methOR differences. In comparison, both pooled SD and
methOR have an influence on power estimated using the
Wilcoxon test. Greatest power can be achieved with
smaller pooled SD and at highest methOR.
To further explore the influence of methylation variance
on power, we selected permutations with the same 20 cases
Figure 4. Power of discordant twin EWAS. Estimates are shown for the
twin (solid lines) and case-control (dashed lines) designs for a range of
sample sizes and mean differences at a significance level of 0.05
(A, upper panel) and 1 106 (B, lower panel). Each line represents the
power curve under different sample sizes from 10 to 100 pairs of twins,
or pairs of cases and controls.
Table 2. Sample size requirements for 80% power in EWAS
twin and case-control designs
Diff Twin Case-control
P<0.05 P<1106 P<0.05 P<1106
t-testa Wilcoxb t-testa Wilcoxb t-testc Wilcoxd t-testc Wilcoxd
7% 30 30 178 178 37 37 211 211
8% 25 25 145 149 30 30 169 169
9% 20 20 117 117 24 24 137 137
10% 17 18 98 102 20 21 112 110
11% 15 15 81 83 17 18 96 95
12% 13 13 71 71 15 16 80 80
13% 11 12 63 69 13 13 70 70
14% 10 11 55 62 11 13 61 63
15% 9 10 50 57 10 11 54 57
Diff, mean methylation difference between affected and unaffected
individuals.
at test, paired t test.
bWilcox, Wilcoxon signed-rank test.
ct test, two-sample t test.
dWilcox, Wilcoxon rank-sum test.
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and 20 controls at a 10% methylation mean difference,
but only using simulations where the variance of cases was
not equal to that of the controls. The major difference be-
tween the equal and unequal variance t test is in the de-
nominator of the t statistic and degrees of freedom. In the
unequal variance test, the variance between groups was
calculated by:
SD
Case Control ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SDCase2
NCase
þ SDControl
2
NControl
s
Power estimates in the unequal variance case-control simu-
lations were categorized using this pooled standard
deviation into four groups (0.040–0.042, 0.042–0.044,
0.044–0.046 and 0.046–0.048), and using methOR into
six groups (1.62–1.64, 1.64–1.66, 1.66–1.68, 1.68–1.70,
1.70–1.72 and 1.72–1.74). Furthermore, we also con-
sidered which group (cases or controls) had the greater
variance; that is, either the variance in cases was greater
than that in controls, or the variance in cases was smaller
than that in controls. Compared with the simulations with
equal variances between the groups, the power estimations
from the unequal variance results were quite similar for the
t test (Supplementary Figure 1, left panel, available as
Supplementary data at IJE online). It is easier to reach
greater power when the variance in the cases is smaller
Figure 5. DNA methylation variance and correlation can impact EWAS power. Case-control power estimates (A, upper panel) are shown under differ-
ent pooled SDs and methORs at a fixed mean difference¼10% using parametric (left panel) and nonparametric (right panel) test statistics. MZ twin
power estimates (B, lower panel) are shown under different pooled SDs and correlation coefficients at a fixed mean difference¼ 9% using parametric
(left panel) and nonparametric (right panel) test statistics.
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than that in controls, and a more distinct pattern is found
using the Wilcoxon test under the same parameter settings
(Supplementary Figure 1, right panel, available as
Supplementary data at IJE online). Similarly to the equal
variance results, the methOR and pooled variance
impact on power (Supplementary Figure 2, available as
Supplementary data at IJE online). These results also high-
light the importance of choosing the appropriate analytical
method across the equal variance t test, the unequal vari-
ance t test and the Wilcoxon test.
DNA methylation variance and twin correlation
can influence power in the EWAS twin design
The impact of methylation variance on power in the case-
control design suggests that similar effects may exist in the
twin design. We therefore assessed power in the EWAS
twin design by considering the pooled SD of the DNA
methylation signal in the twin sample, as well as the correl-
ation in methylation between co-twins (Figure 5B). We
performed permutations by varying the pooled SD and cor-
relation, at a set methylation difference of 9% in 20 pairs
of twins. Because 9% methylation difference can corres-
pond to a range of methORs (from 1.30 to 2.44) in the
case-control design, which can also impact on power, we
further restricted the permutations to give a set
methOR¼ 1.67. Power was estimated at nominal signifi-
cance by categorizing pooled SD into four groups (0.6–0.7,
0.7–0.8, 0.8–0.9 and 0.9–1.0), and the correlation into six
groups (0.19–0.25, 0.25–0.30, 0.30–0.35, 0.35–0.40,
0.40–0.45 and 0.45–0.63). The smallest pooled SD results
in greatest power and, under the same pooled SD, permu-
tations with higher twin correlation result in greater
power. Compared with the t test, the Wilcoxon test gives
slightly lower power under moderate pooled SD, but the
Wilcoxon test can outperform the t test under larger
pooled SD. Smaller pooled SD, greater mean difference
and greater Spearman’s correlation within twins can result
in greater power.
Discussion
Statistical power and sample size are crucial to EWAS
design and interpretation. Here, we estimate power and
sample size limitations for two most commonly applied
EWAS designs under a number of key assumptions. EWAS
power has previously been explored in the case-control
context, but our results provide a first characterization of
power for the disease-discordant MZ twins EWAS design
across a range of epigenetic disease models.
MZ twins share nearly all of their genetic variants, are
matched for age, gender and cohort effects, and have
similar in utero and maternal effects and many early-life
environmental factors. All of these factors have either been
shown or are hypothesized to influence DNA methylation
levels throughout the genome. Therefore, MZ twins are a
much more homogeneous sample relative to genetically
heterogeneous unrelated individuals who are exposed to
different environments throughout life, and correspond-
ingly MZ twins have been shown to have much more simi-
lar levels of DNA methylation compared with dizygotic
(DZ) co-twins and unrelated pairs of individuals.3,33 It is
difficult to incorporate all of these factors in a simulation
study, therefore in an attempt to minimize some of these
effects, we assumed that all individuals in our study were
the same age and gender and were exposed to similar
cohort effects. This will bias the case-control sample to-
wards homogeneity and may give inflated power estimates
for the case-control design. Therefore, we cannot directly
compare the power estimates of case-control and twin
designs. The EWAS case-control and EWAS twin designs
are complementary to each other and can be used jointly to
identify the cause of the identified disease-associated
DMR. The twin design can be used to identify disease-
related DMRs that are either caused by stochastic or envir-
onmental factors, or that are a consequence of the disease.
In contrast, samples of unrelated individuals provide the
option to integrate genetic and DNA methylation datasets
to explore potential genetic impacts on the trait that are
mediated by methylation.
Our findings build on two previous studies that explore
power in the case-control design.27,28 In general, the case-
control power estimates and conclusions are consistent
with previous results.27,28 For example, using 200 cases
and 200 controls, a methOR of 1.49 and a mean difference
of 7.2% previously resulted in 16% power under the Wald
test.27 The closest scenarios in our study were using 200
cases and 200 controls, simulating a methOR between
1.45 (mean difference¼ 6.4%) and up to methOR of 1.5
(mean difference¼ 7.0%), which resulted in power
between 18% and 67% under the Wilcoxon test, respect-
ively. Although power is close to previous estimates, there
is a divergence which could be explained by the different
composition of the underlying DNA distributions. Both
previous power studies proposed that the single-locus
DNA methylation distribution is composed by a mixture
distribution, either a Uniform-Normal mixture28 or single
or combined Beta distributions,27 whereas we assumed
that the cases follow predominantly a single Beta distribu-
tion and the controls remained un-methylated. Our as-
sumption was based on published profiles from 172
healthy female subjects3 measured by the Illumina 27K
array, where 69% (n¼ 24 641) of the autosomal CpGs
were un-methylated and the majority of methylation
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distributions on each locus followed single Beta distribu-
tion with small standard deviation (85% of probes with
SD< 0.05). Therefore, as previously noted, the shape of
the underlying single-locus DNA methylation distribution
will play a role in power.
One of the major characteristics of the DNA methyla-
tion distribution is the variance in DNA methylation. DNA
methylation variance has previously been shown to impact
power,28 and we confirm these results not only in the case-
control design but also in the twin EWAS design. Another
conclusion that is consistent across studies27 is that the
methOR measure of epigenetic effect appears to correlate
better with power than the mean difference effect. Finally,
the similarity in DNA methylation profiles within pairs of
genetically identical twins can impact on EWAS power in
the twin design.
Some of the limitations of our study arise from the
major assumptions. One of these is that DNA methylation
occurs prior to disease onset and is mitotically stable.
Recent genome-wide data on longitudinal stability of DNA
methylation marks show that there is great variability in
longitudinal stability of methylation marks across the gen-
ome and with respect to age of the individual.4 Another
key assumption is that we explore DNA methylation pro-
files in the tissue that is most relevant to the disease. For
many diseases, access to clinically relevant tissues is not
feasible and surrogates such as whole blood are often used
in EWAS. Both tissue-shared and tissue-specific DNA
methylation profiles exist across the genome, and model-
ling these effects in our epigenetic disease susceptibility
models is difficult with limited empirical data. A third
overly simplistic assumption is to model the similarity in
DNA methylation profiles within MZ twins as a range of
correlations from empirical estimates.3 Several reports
have identified and replicated twin-based DNA
methylation heritable regions in the genome,3,31,33 and
have clearly shown that MZ twins have more similar
methylation profiles than unrelated individuals.3 However,
the precise structure of this correlation along the
genome varies.31 Lastly, we considered power and sample
size estimates under models where a single CpG site is associ-
ated with the phenotype. It is possible that multiple CpG sites
impact on the phenotype, either as an epi-haplotype (where
taking into account co-methylation may be informative), or
under models of CpG-interaction. For many of these assump-
tions, the relevant parameters are difficult to estimate because
of lack of in-depth data.
In summary, using comprehensive power calculations
we provide power limits of EWAS for the case-control and
discordant twin designs under a range of models and sev-
eral key assumptions. Our findings can help EWAS design
and interpretation.
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